DIRS.INFO The most relevant business & tech news

☆ Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
▼ + stars: | 2024-05-07 | by ( Eduardo Munoz | ) www.cnbc.com time to read: +3 min

A highly popular group of weight loss and diabetes drugs is still hard to find in the U.S. The dominant manufacturers of those treatments, Eli Lilly and Novo Nordisk , are making progress toward changing that. Patients using current autoinjectors for weight loss and diabetes drugs go through four different pens per month. Eli Lilly expects supply for Zepbound, Mounjaro and other incretin drugs to remain "quite tight" in the near- to mid-term as demand remains high, Ashkenazi said. On the day Eli Lilly reported earnings, shares of the company jumped more than 5% on the raised guidance and supply updates.

Persons: Eli Lilly, Anat Ashkenazi, There's, Ashkenazi, David Ricks, —, Lilly, Chris Schott Organizations: U.S, Novo Nordisk, Nexus Pharmaceuticals, JPMorgan Locations: North Carolina, Indiana, Ireland, Germany, Europe, U.S

☆ Eli Lilly assures investors it can overcome the high-quality problem of too much demand
▼ + stars: | 2024-04-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

Eli Lilly 's raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. At their highs of the morning, shares of Eli Lilly traded above their all-time closing high of $792.28 set on March 4. In general, the more-bullish financial outlook helps make Eli Lilly's high price-to-earnings ratio coming into earnings more tolerable for investors. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: Eli Lilly, Eli Lilly's, Lilly, Jim Cramer, Lilly's, Jim, Anat Ashkenazi, Zepbound, It's, Ashkenazi, Dave Ricks, donanemab, Jim Cramer's, Eli Lilly’s, Brendan McDermid Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, U.S, Drug Administration, Nexus Pharmaceuticals, CNBC, FDA Locations: Eisai, Zepbound, Trulicity, Wisconsin, New York City, U.S

☆ Eli Lilly CEO on weight loss drugs outlook: Our top priority is making more product
▼ + stars: | 2024-04-30 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO on weight loss drugs outlook: Our top priority is making more productEli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's weight loss drugs, growth outlook, and more.

Persons: Eli Lilly, David Ricks

☆ Eli Lilly soars 8% after Q1 earnings reveal surging popularity for its Zepbound weight-loss drug
▼ + stars: | 2024-04-30 | by ( Matthew Fox | ) www.businessinsider.com time to read: +4 min

The world's biggest healthcare company said it experienced surging demand for its GLP-1 Zepbound weight loss drug. Eli Lilly raised its 2024 revenue guidance, suggesting that the supply shortage of its weight loss drug may soon ease. The results showed soaring demand for its GLP-1 weight loss drug Zepbound, and the revenue guidance increase suggests that ongoing supply shortages of the drug may soon ease. "We have approximately 67% access in the commercial segment," Eli Lilly CFO Anat Ashkenazi said on the company's earnings call. Eli Lilly is looking to expand its indications of Zepbound so it can treat more health problems, including sleep apnea.

Persons: Eli Lilly, —, Zepbound, David Ricks, Eli Lilly's, Anat Ashkenazi, Ashkenazi, LLY, JPMorgan, JPMorgan isn't Organizations: Service, JPMorgan Locations: America

☆ Here are Friday's biggest analyst calls: Nvidia, Tesla, Apple, Rivian, Micron, Microsoft, Eli Lilly, Amazon & more
▼ + stars: | 2024-03-15 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

Citi upgrades Thor Industries to buy from neutral Citi said it see a "favorable event path" for the RV company. " Citi initiates Pure Storage as buy Citi said in its initiation of Pure Storage that the data storage company is an AI beneficiary. Citi reiterates Apple as buy Citi said it's standing by its buy rating on shares of Apple. Bank of America reiterates Amazon as buy Bank of America said it's bullish heading into Amazon's Spring Sales event next week. Citi reiterates Micron as buy Citi raised its price target on the stock to $150 per share from $95 and says it's bullish heading into earnings next week. "

Persons: Piper Sandler, Piper, Morgan Stanley, RSG, Cummins, Baird, Nvidia, JPMorgan, Tesla, Telsey, Todd Vasos, it's, Stellantis, Five9, PBF, DINO, Truist, Eli Lilly, LLYs, Dave Ricks, Patrik Jonsson Organizations: EV, Bank of America, Adobe, Citi, Thor Industries, Morgan Stanley downgrades Republic Services, UBS, Cummins, CMI, Microsoft, Nvidia, JPMorgan, Guggenheim, Apple, Worldwide, " Bank of America, Micron, Catalyst Watch, RBC, UFC, WWE, Inc, Valero Energy, Sinclair, of America, Entertainment, Golden Entertainment, Diabetes, Obesity Locations: Snowflake, F4Q24, China, Nevada

☆ Jim Cramer: Viking Therapeutics' weight-loss data not enough to dethrone Eli Lilly in GLP-1s
▼ + stars: | 2024-02-27 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Tuesday downplayed the competitive risk to Eli Lilly — a longtime holding in his Charitable Trust — presented by Viking Therapeutics ' new weight-loss drug data. Currently, Eli Lilly and Wegovy maker Novo Nordisk are the dominant players in the GLP-1 category. Eli Lilly and Novo Nordisk are far larger, worth around $733 billion and $550 billion as of Tuesday. Eli Lilly shares, among the best performers in the S & P 500 this year, fell slightly Tuesday. Cramer's Charitable Trust, the portfolio used by the CNBC Investing Club , has long owned Eli Lilly.

Persons: CNBC's Jim Cramer, Eli Lilly —, —, Eli Lilly, Cramer, Eli Lilly's tirzepatide, David Ricks, Lilly's, retatrutide Organizations: Viking Therapeutics, Novo Nordisk, Viking, Leerink Partners, Charitable Trust, CNBC Locations: Lilly

Eli Lilly rode soaring demand for diabetes and weight-loss treatments to a better-than-expected finish in 2023, and the drugmaker expects momentum to carry into the new year. Lilly said on Tuesday that revenue could climb as much as 22% this year, as star sellers like the diabetes drug Mounjaro and its new weight-loss counterpart, Zepbound, gain market share. Mounjaro sales jumped 65% to $2.21 billion in the fourth quarter compared with the third quarter. Doctors also prescribe that drug off-label for weight loss, which is one of the hottest areas of pharmaceutical sales. The share price for Indianapolis-based Eli Lilly and Co. has climbed over 400% since the start of the decade.

Persons: Eli Lilly, Lilly, Doctors, David Ricks, “, ”, FactSet, donanemab Organizations: Company, Revenue, Drug Administration, Indianapolis Locations: Mounjaro, North Carolina

☆ January was great for stocks — here are our top 5 performers for the month
▼ + stars: | 2024-02-02 | by ( Morgan Chittum | ) www.cnbc.com time to read: +5 min

We took advantage of the hot streak in stocks, making small sales throughout the month. NVDA YTD mountain Nvidia (NVDA) year-to-date performance 1. PANW YTD mountain Palo Alto Networks (PANW) year-to-date performance 2. META YTD mountain Meta Platforms year-to-date performance 3. CRM YTD mountain Salesforce (CRM) year-to-date performance 4.

Persons: Jerome Powell, Mark Zuckerberg, Jim Cramer, Palo, Cowen, Salesforce, Eli Lilly, LLY, Jefferies, David Ricks, Jim Cramer's, Jim, Brendan Mcdermid Organizations: Dow, Nasdaq, Big Tech, Club, Federal Reserve, Nvidia, Meta, Palo Alto Networks, Microsoft, JPMorgan, Palo, Facebook, CNBC, Traders, New York Stock Exchange Locations: Palo, New York City, U.S

☆ How Eli Lilly plans to fix the supply snag for its blockbuster diabetes drug
▼ + stars: | 2024-01-26 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

They're also at the heart of our investment thesis in Eli Lilly, a longtime Club holding. Shares of Eli Lilly have soared nearly 80% over the past 12 months, including a more-than-5% gain in January alone. In November, Eli Lilly indicated it was on track to meet the goal, which also was made possible by upgrades to existing facilities. Eli Lilly has used KwikPen technology for other diabetes treatments, such as insulin injections, for many years. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.

Persons: Eli Lilly, —, Eli Lilly's, They're, FactSet, Lilly's, Dave Ricks, Ricks, Lilly, there's, Morgan Stanley, Eli, Jim Cramer's, Jim Cramer, Jim, George Frey Organizations: CNBC, FDA, Novo Nordisk, JPMorgan Healthcare Conference, Research, Barclays, RTP, —, U.S, JPMorgan, Bloomberg, Getty Locations: Danish, Indianapolis, North Carolina, Carolina, Concord , North Carolina, Germany, U.S, Australia, Canada, KwikPen, Provo , Utah

☆ The portfolio's 6 best-performing stocks since the December Monthly Meeting
▼ + stars: | 2024-01-24 | by ( Morgan Chittum | ) www.cnbc.com time to read: +6 min

Here then are our top stocks since our last meeting, from the Dec. 19 market close through Tuesday's trading session. NVDA YTD mountain Nvidia (NVDA) year-to-date performance Coming in at No. META YTD mountain Meta Platforms year-to-date performance Meta finished third, with shares rising 9.9% as Wall Street analysts anticipate a brighter outlook for the digital advertising market in 2024. LLY YTD mountain Eli Lilly (LLY) year-to-date performance Fourth on our list of top performers is Eli Lilly . GOOGL YTD mountain Alphabet (GOOGL) year-to-date performance Alphabet and Broadcom shares both jumped 7.6% over the last month, tying for No.

Persons: Dow, Bausch, Mark Zuckerberg, We're, Exchange Commission's, Palo, Jim Cramer, Meta, Cowen, there's, Jim, Eli Lilly, LLY, David Ricks, Jim Cramer's, Stocks, Spencer Platt Organizations: Big, Apple, Barclays, Bausch Health, Nvidia, Meta, Palo Alto Networks, Palo, Securities, Exchange, SEC, Microsoft, JPMorgan, Microsoft's, Wall, U.S, Facebook, Jefferies, Broadcom, CNBC, Traders, New York Stock Exchange, Getty Locations: Big Tech, U.S, Palo, New York City

☆ 4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
▼ + stars: | 2024-01-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +12 min

We will go over them – but first, let me talk about what I learned at last week's JPMorgan Health Care Conference that I attended in San Francisco, and what it means to your portfolio. We know health care has a lot of angles too it. The previous CEO Roz Brewer was from Starbucks and struggled with the role that Walgreens plays in health care. You have to be following the transformation of Bristol-Myers, which is opening its wallet to buy a host of drug companies, including anti-psychotic firm Karuna. Health care is the way to go.

Persons: Regeneron, Pfizer, Eli Lilly, Dave Ricks, Lilly, donanemab, Lilly's, Zepbound, it's, Abbott, It's, Roche, Merck, Myers, ABT, Robert Ford, Tim Wentworth, He's, Roz Brewer, Wentworth, he'll, Brewer wasn't, Bob Bradway, Amgen, Vas Narasimhan, Sandoz, Karuna, Medtronic, Hugo, Morgan Stanley, Wells, Covid, Cramer's, Jim Cramer, Jim, Las Vegas Brendan Smialowski Organizations: Abbott Labs, Covid, Novartis, Amgen, Walgreens Boots Alliance, JPMorgan Health Care Conference, Humana, Drug Administration, Novo Nordisk, Dickinson Co, Bristol, Myers Squibb, Pfizer, Department, WBA, Walgreens, Starbucks, -, pharma, Merck, Keytruda, Horizon Therapeutics, Federal Trade Commission, Myers, BD, CVS Health, JPMorgan, Cramer's Charitable, CNBC, Consumer, AFP, Getty Locations: San Francisco, GLP, North Carolina, Europe, Cencora, Amgen, West, Bristol, Target, Las Vegas

TUSCALOOSA, Ala. (AP) — Kalen DeBoer stood at a lectern, only a few feet from Nick Saban, and enthusiastically embraced the chance to both replace and learn from his larger-than-life predecessor. All that makes it easier to be the guy who replaces the guy who brought six national championships to Tuscaloosa in 17 years. A huge photo of Saban and players hoisting a national championship trophy hung on the wall behind DeBoer as he talked to reporters. DeBoer spoke with Saban on the phone Friday morning and called him again the next morning. Still, he wiped away tears while talking about leaving his Washington players who made it to the brink of a national title.

Persons: Kalen DeBoer, Nick Saban, Saban, ”, “, ” DeBoer, Denny, Terry, Stuart R, Bell, ” Bell, DeBoer, ” DeBoers, Dezz Ricks, Isaiah Bonds, Greg Byrne's, Byrne, Nicole, you’d, ” Byrne Organizations: “, Bryant, Tide, University, Alabama, ESPN, Associated, NAIA, Sioux, Fresno State, Huskies, Washington, Southeastern Conference, College Football Playoff, DeBoer, LSU, AP Locations: TUSCALOOSA, Ala, Washington, Tuscaloosa, DeBoer, South Dakota, alma, Alabama

☆ Ozempic maker plans manufacturing blitz as market for the drug is expected to top $100 billion in 2030
▼ + stars: | 2023-11-23 | by ( Jake Swearingen | ) www.businessinsider.com time to read: +2 min

Novo Nordisk makes Ozempic and Wegovy, two hit drugs that treat obesity. In the past two weeks, it's announced more than $8 billion in manufacturing investments. AdvertisementNovo Nordisk, maker of the popular anti-obesity drugs Ozempic and Wegovy, is investing billions to ramp up production capacity amid surging demand. The move comes just after Novo Nordisk unveiled plans to shell out over $6 billion to expand manufacturing capacity in Denmark. That money will go toward increasing production capacity for semaglutide, the key ingredient in Ozempic and related medications.

Persons: it's, —, Ozempic, Emmanuel Macron, Eli Lilly, David Ricks, Lilly, Goldman Sachs Organizations: Novo Nordisk, Service Locations: France, Chartres, Denmark, Europe, Novo

☆ Weight-loss drugs just got cheaper — and better
▼ + stars: | 2023-11-11 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +7 min

Eli Lilly just debuted its powerful new weight-loss drug, Zepbound. Normally, when newer, better drugs are introduced, they match the price of similar drugs already available or come at a premium . Eli Lilly and Novo Nordisk have said that about 50 million people have some level of insurance coverage for weight-loss drugs. But some experts were skeptical, because employers and insurers don't typically pay the list price for drugs. Craig Garthwaite, an economist at Northwestern University, argued competition will drive the net prices of weight-loss drugs lower still.

Persons: Eli Lilly, —, Wegovy, LLY, It's, Mike Mason, coinsurance, Antonio Ciaccia, Crystal, We're, David Risinger, Dave Ricks, David Ricks, Eli Lilly's Mason, Mason, Craig Garthwaite, Garthwaite Organizations: Service, pharma, Nordisk's Wegovy, Ozempic, Deutsche Bank, 46brooklyn Research, Crystal Cox, Novo Nordisk, Zepbound, Wegovy, American Enterprise Institute, Northwestern University Locations: Mounjaro

☆ AstraZeneca adds player to obesity drug race, but Eli Lilly remains in the lead
▼ + stars: | 2023-11-10 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

Eli Lilly (LLY) remains our favorite way to play the weight-loss drug market, despite a new entry this week from AstraZeneca (AZN). Eli Lilly shares had their worst day of the year Thursday, falling 4.5% in the session to close at $591.32. AstraZeneca's encroachment on turf currently dominated by Eli Lilly and Danish rival Novo Nordisk (NVO) may have contributed to Thursday's declines. That approval, despite being widely expected, pushed Eli Lilly to an all-time closing high Wednesday, at $619.13 per share. Our desire to own Eli Lilly over Novo Nordisk hinges, in part, on our confidence in Eli Lilly's other treatment opportunities, such as in Alzheimer's.

Persons: Eli Lilly, Jim Cramer, Jim, Lilly's, Eli Lilly's tirzepatide, Zepbound, Novo's, Eli Lilly's, Eli Lilly's GLP, Dave Ricks, Lilly, Ricks, AstraZeneca's, ECC5004, retatrutide, Jim Cramer's, David Ricks, Eli Lilly Scott Mlyn Organizations: AstraZeneca, Novo Nordisk, American Heart Association, Novo Nordisk's semaglutide, CNBC, Reuters, Citigroup Locations: Danish, GLP, North Carolina, Novo, Denmark, Zepbound, Alzheimer's

☆ Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom. Here's why, analyst says
▼ + stars: | 2023-11-10 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +6 min

Does Eli Lilly deserve to trade at a premium to Novo Nordisk shares? LLY YTD mountain Eli Lilly shares since the start of the year. According to Shin, Lilly deserves a premium to Novo Nordisk because its portfolio is more diverse and it has less exposure to insulin. NVO YTD mountain Novo Nordisk shares year to date In the coming weeks, Lilly will start rolling out Zepbound to patients. Novo Nordisk is scheduled to release the full results of its Select cardiovascular trial at the American Heart Association conference.

Persons: Eli Lilly, James Shin, Shin, Lilly, We're, Lilly's, Zepbound, Wegovy, Chris Schott, Karsten Munk Knudsen, Novo, Schott, AstraZeneca, Eccogene, David Ricks, — CNBC's Michael Bloom Organizations: Novo Nordisk, Deutsche Bank, Biotech, Pharma, Centers for Disease Control, Novo, CNBC, American Heart Association Locations: U.S, GLP, Novo, Denmarkt

☆ Eli Lilly CEO: We know there's high demand for weight-loss drugs and we're ready to meet it
▼ + stars: | 2023-11-09 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO: We know there's high demand for weight-loss drugs and we're ready to meet itDavid Ricks, Eli Lilly CEO, joins 'Closing Bell Overtime' to talk the FDA's approval of its new weight-loss drug, keeping up with demand for the drug, competition in the space and more.

Persons: Eli Lilly, David Ricks

☆ Eli Lilly's rally on blowout Mounjaro sales signals a new leg higher for the stock
▼ + stars: | 2023-11-02 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

LLY YTD mountain Eli Lilly's year-to-date stock performance. Investors are understandably cheering the results, sending Eli Lilly shares higher by more than 4%. "Eli Lilly today is beginning its next leg of going up," Jim Cramer said during Thursday's Morning Meeting . The most important line item was Mounjaro sales, which cleared Wall Street's high bar. Excluding that divestiture and the $387 million in Covid antibody sales in the year-ago quarter, Eli Lilly's sales grew 24% on an annual basis — a highly respectable figure.

Persons: Eli Lilly, LLY, Mounjaro, it's, Eli Lilly's, Jim Cramer, Jim, It's, Novo's, Lilly, We're, Dave Ricks, Ricks, Trulicity, Anat Ashkenazi, Lilly —, Ashkenazi, Jim Cramer's, David Ricks, Eli Lilly Scott Mlyn Organizations: Drug Administration, FDA, Novo Nordisk, CNBC, Management, Dice Therapeutics, Therapeutics Locations: North, Concord , North Carolina, U.S, Indianapolis

☆ Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook
▼ + stars: | 2023-11-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Eli Lilly on Thursday reported third-quarter revenue and adjusted earnings that topped estimates on strong demand for its diabetes drug Mounjaro, but slashed its full-year profit guidance due to charges primarily related to its recent acquisitions. Eli Lilly recorded pre-tax "in-process research and development" charges of $2.98 billion, which are primarily related to a slew of recent buyouts, including DICE Therapeutics, Versanis Bio and Emergence Therapeutics AG. "This is essentially the future value of business development deals we have done," Eli Lilly CEO David Ricks said on CNBC's "Squawk Box" on Thursday. But Eli Lilly reiterated its full-year revenue forecast of between $33.4 billion and $33.9 billion. With a market cap of roughly $526 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.

Persons: Eli Lilly, Jardiance, David Ricks Organizations: LSEG, Therapeutics, U.S Locations: Mounjaro, Wednesday's

☆ Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.
▼ + stars: | 2023-11-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly on Thursday said supply of its blockbuster diabetes drug Mounjaro has improved in the U.S. after months of widespread shortages. During an earnings call Thursday, Eli Lilly executives said the company experienced tight supply for Mounjaro throughout most of the third quarter. But U.S. product shipments of Mounjaro have recently increased, and inventory levels at U.S. drug wholesalers have improved, according to Eli Lilly CFO Anat Ashkenazi. Eli Lilly has also invested more than $3 billion to build two new manufacturing sites in its home state of Indiana. Eli Lilly's main rival in the weight loss drug space, Novo Nordisk , is still navigating its own supply constraints of diabetes drug Ozempic and obesity treatment Wegovy.

Persons: Eli Lilly, Mounjaro, Eli Lilly's, Anat Ashkenazi, Ashkenazi, David Ricks, Ricks, we're, Wegovy, Eli Lilly's Mounjaro Organizations: Novo Nordisk, Pharmacy, Food, Pfizer Locations: Provo , Utah, U.S, North Carolina, Indiana, Novo

☆ Eli Lilly CEO David Ricks on Q3 earnings beat, Mounjaro strength
▼ + stars: | 2023-11-02 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO David Ricks on Q3 earnings beat, Mounjaro strengthEli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported third-quarter revenue and adjusted earnings that topped expectations, lifted by $1.4 billion in sales from its blockbuster diabetes drug Mounjaro, and more.

Persons: Eli Lilly, David Ricks, Mounjaro

The Eagles (5-1) got one more chance to win when they got the ball back, but the defense stiffened — as it had all game. Hurts finished 28 of 45 for 280 yards and one touchdown but had three picks against a Jets defense that was missing starting cornerbacks Sauce Gardner and D.J. By rule, only the player who lost the ball could recover the forward fumble in the end zone, so it was ruled that it was the Jets' ball on the 1. The Eagles took advantage of some poor tackling by the Jets in the second quarter. Jets: Rookie RG Joe Tippmann didn't come back after injuring his right thigh on the first play of the second quarter.

Persons: — Breece, Tony Adams, Jalen, Philadelphia —, Zach Wilson, Randall Cobb, DeVonta Smith, Wilson, Gardner, D.J, Reed, Greg Zuerlein, Adams, Bryce Hall, Quinnen Williams, Quincy Williams, D'Andre Swift, Brown corralled, Robert Saleh, Brown, Jake Elliott, —, C.J, Mosley, Swift, RODGERS, Aaron Rodgers, Sauce Gardner, Woody Johnson, Travis Kelce —, Taylor Swift, Jason Kelce, Lane Johnson, didn't, Jack Driscoll, Eli Ricks, Reed Blankenship, Joe Tippmann didn't, Wes Schweitzer, ___ Organizations: —, New York Jets, Philadelphia Eagles, Jets, Eagles, Philadelphia, Adams, MetLife, NFL, New, Kansas City, Lazard . Jets, Miami Dolphins, Giants Locations: RUTHERFORD, N.J, New York

☆ Why the hydrogen tax credit has become a lightning rod for controversy
▼ + stars: | 2023-10-13 | by ( Catherine Clifford | In Catclifford | ) www.cnbc.com time to read: +16 min

The proposed tax credit, 45V, is meant to turbocharge the production of low-emissions hydrogen. "The IRA's section 45V production tax credit is the most generous clean hydrogen subsidy in the world," Jesse Jenkins, professor of macro-scale energy systems at Princeton University, told CNBC. John Macdougall | Afp | Getty ImagesThe adjudication of the hydrogen tax credit has become about more than just the hydrogen tax credit, too. The amount of the hydrogen tax credit, which is available for 10 years, depends on the emissions generated in making hydrogen. If hydrogen is produced without releasing any carbon emissions, the tax credit is maxed out at $3 per kilogram of hydrogen.

Persons: that's, It's, Jesse Jenkins, John Macdougall, Wilson Ricks, Jenkins, Ricks, Rachel Fakhry, electrolyzers, Andriy Onufriyenko, Eric Guter, Josef Kallo, H2FLY, Guter, Phil Musser, Shannon Angielski, Angielski, Shi, Fakhry Organizations: Istock, Treasury, Princeton University, CNBC, Daimler Truck Holding, Afp, Getty, Energy, Research, Princeton, Natural Resources Defense Council, Power, Singularity, Air Products, Bloomberg, Air, Products, Hydrogen Company, European, EU, NextEra Energy, Hydrogen Future Coalition, BP, Duke Energy, Exxon Mobile, General Electric, Siemens Energy, American, Shell, Hydrogen, Coalition Locations: Biden's, United States, U.S, Berlin, additionality, Maribor, Slovenia, Oxagon, Saudi Arabia, Wilbarger County , Texas

☆ Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion
▼ + stars: | 2023-09-09 | by ( Bob Woods | ) www.cnbc.com time to read: +13 min

In this article LLYNOVO.B-DK Follow your favorite stocks CREATE FREE ACCOUNTOzempic drug to treat diabetes. Since Wegovy and Mounjaro have been on the market, "neither company can make the drug fast enough," she said. The Food and Drug Administration approved Ozempic in 2017 for diabetes and Wegovy in 2021 to treat obesity. Mounjaro, introduced in 2022 to treat diabetes, contains GLP-1, plus GIP, a similar appetite suppressor that can lead to weight loss. Coverage for Mounjaro ($1,023 per month) to treat diabetes varies based on an individual's insurance plan and drug benefits.

Persons: Eli Lilly, Novo's, Lilly's, Emily Field, Lilly, David Ricks, CNBC's Jim Cramer, Ozempic, Novo, Mounjaro, George Frey, Lars Fruergaard Jorgensen, Wajahat Mehal, Tom Carper, Bill Cassidy of, We've, Camilla Sylvest, there's, Sylvest, Cowen, What's, It's, Mike Mason, Amgen, Emmanuel Papadakis Organizations: Novo Nordisk, Pfizer, Amgen, Barclays, Nordisk, Drug Administration, Mounjaro, SVB Securities, Food and Drug Administration, Pharmacy, Reuters Novo, Novo, Wegovy, European Union, Medicare, Yale School, Metabolic, Congressional Black Caucus, CDC, pharma, American Medical Association, , Big Pharma, American Diabetes Association, Deutsche Bank Locations: Lilly, Denmark, Provo , Utah, U.S, European, Delaware, Bill Cassidy of Louisiana, Novo, Kalundborg, Hillerød, Boone County , Indiana

☆ Obesity drugs take brakes off Big Pharma’s growth
▼ + stars: | 2023-08-08 | by ( Robert Cyran | ) www.reuters.com time to read: +4 min

That’s what Eli Lilly (LLY.N) did in the second quarter, thanks to demand for its diabetes and weight loss drug Mounjaro. While doctors are currently free to prescribe Mounjaro for obesity, insurers and governments typically won’t pay for what some still insist is a vanity treatment. Even so a regulatory green light, and clear evidence that these drugs have tangible health benefits, will help loosen purse strings. The brakes are off these firms’ growth, and investors are counting on them remaining so. Mounjaro, the company’s diabetes drug, brought in revenue of $980 million, compared to $16 million a year ago.

Persons: Eli Lilly, LLY.N, Lilly, That’s, David Ricks, Mounjaro, Peter Thal Larsen, Sharon Lam Organizations: Reuters, Novo Nordisk, U.S . Food, Drug Administration, Merck, Investors, Thomson Locations: Danish, U.S, Novo

Search resuls for: "ricks"

25 mentions found